30 Day Trial

Embody Gains Additional Funding for ACL Repair

Share:

Embody is receiving a $2.5 million Phase II Small Business Innovation Research award through the Defense Advanced Research Projects Agency (DARPA), bringing its total DARPA funding to $14.35 million. The award will support development and clinical assessment of MICROBRACE™ ACL technology for anterior cruciate ligament repair.

MICROBRACE for ACL is a stand-alone, off-the-shelf solution designed to immediately restore mechanical stability to the knee joint and gradually remodel over time.

"A collagen implant that provides strength long enough to protect a surgical repair or reconstruction yet remodels over time is quite desirable. There are numerous potential applications for the Embody MICROBRACE including ACL surgery," commented  Kevin F. Bonner, M.D., an orthopedic surgeon and Director of the Research Foundation at The Jordan-Young Institute in Virginia Beach, Virginia.

Embody is developing biomaterials with an initial focus on orthopedic applications such as Achilles, rotator cuff and knee ligament repair. Previously, the company has raised funding from cultivate(MD) and DARPA.